Phase 1 trial of ZZ06, an EGFR mAb, in advanced EGFR-positive solid tumors.

This open-label, multicenter study determines the maximum tolerated dose and characterizes safety, pharmacokinetics, immunogenicity, pharmacodynamics, and preliminary antitumor activity of ZZ06 as a single agent in adult patients with advanced EGFR-positive solid tumors ineligible for standard therapies. Patients receive twice-weekly infusions at escalating doses over 28-day cycles with treatment continued based on tolerability, and the trial is sponsored by Changchun Intellicrown Pharmaceutical Co. LTD.